Skip to main content Back to Top
Advertisement

1/30/2024

Olanzapine Pamoate Extended Release Suspension for Injection

Products Affected - Description

    • Zyprexa Relprevv intramuscular powder for suspension for injection, H2 Pharma, 210 mg extended release, single-dose vial convenience kit, NDC 00002-7635-11
    • Zyprexa Relprevv intramuscular powder for suspension for injection, H2 Pharma, 300 mg extended release, single-dose vial convenience kit, NDC 00002-7636-11
    • Zyprexa Relprevv intramuscular powder for suspension for injection, H2 Pharma, 405 mg extended release, single-dose vial convenience kit, NDC 00002-7637-11

Reason for the Shortage

    • H2 Pharma did not provide a reason for the shortage.
    • H2 Pharma is the sole supplier of olanzapine extended release suspension for injection.

Available Products

    • There are no presentations available

Estimated Resupply Dates

    • H2 Pharma has all Zyprexa Relprevv presentations on back order and the company estimates a release date of June 2024.

Updated

Created January 30, 2024 by Leslie Jensen, PharmD, Drug Information Specialist. © 2024, Drug Information Service, University of Utah, Salt Lake City, UT.

ADVERTISEMENT

Disclaimer

Drug Shortage Bulletins are copyrighted by the Drug Information Service of the University of Utah and provided by ASHP as its exclusive authorized distributor. ASHP and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, with respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this Bulletin. Neither ASHP nor the University of Utah endorses or recommends the use of any particular drug. Any application of this information for any purpose shall be limited to personal, non-commercial use.

« Back to Drug Shortage Product Bulletins


ahfs logo

Subscribe to AHFS Clinical Drug Information to get direct access to integrated drug shortages content, plus comprehensive and actionable drug information.